NASDAQ · KURA
Healthcare · Biotechnology
$9.88
Up+$0.09 (+0.92%)
Updated Nov 4, 2026, 3:03 AM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · KURA
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
KURA closed at $9.88 after 21 trading sessions, down 6.17% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $9.88 | $10.17 | $9.77 | $9.88 | 1.21M |
| Nov 2, 2026 | $10.28 | $10.335 | $9.765 | $9.79 | 1.72M |
| Oct 30, 2026 | $10.50 | $10.75 | $9.93 | $10.26 | 2.25M |
| Oct 29, 2026 | $10.70 | $10.9557 | $10.50 | $10.56 | 1.59M |
| Oct 28, 2026 | $9.74 | $10.74 | $9.6701 | $10.72 | 2.29M |
| Oct 27, 2026 | $9.66 | $9.90 | $9.535 | $9.90 | 1.71M |
| Oct 26, 2026 | $9.73 | $9.84 | $9.555 | $9.62 | 865.01K |
| Oct 23, 2026 | $9.80 | $9.84 | $9.2831 | $9.61 | 1.56M |
| Oct 22, 2026 | $9.85 | $10.015 | $9.72 | $9.86 | 1.06M |
| Oct 21, 2026 | $10.04 | $10.18 | $9.845 | $9.88 | 1.16M |
| Oct 20, 2026 | $9.45 | $10.2761 | $9.28 | $9.98 | 1.54M |
| Oct 19, 2026 | $9.17 | $9.38 | $8.9279 | $9.36 | 2.16M |
| Oct 16, 2026 | $9.68 | $9.68 | $9.05 | $9.08 | 1.78M |
| Oct 15, 2026 | $9.825 | $9.90 | $9.60 | $9.70 | 1.68M |
| Oct 14, 2026 | $9.70 | $9.86 | $9.57 | $9.61 | 1.83M |
| Oct 13, 2026 | $10.29 | $10.29 | $9.76 | $9.83 | 2.73M |
| Oct 12, 2026 | $10.60 | $10.68 | $10.31 | $10.395 | 1.21M |
| Oct 9, 2026 | $10.52 | $10.68 | $10.38 | $10.60 | 1.47M |
| Oct 8, 2026 | $10.52 | $10.55 | $10.16 | $10.52 | 1.64M |
| Oct 7, 2026 | $10.43 | $10.99 | $10.32 | $10.67 | 1.1M |
| Oct 6, 2026 | $10.75 | $10.885 | $10.34 | $10.53 | 1.31M |
The latest Smart Investors Daily articles mentioning KURA.
Company
Market Activity
Research & News
KURA research
Company profile and research snapshot.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 1, 2026 | JP Morgan | Overweight | — |
| Aug 24, 2026 | Citizens | Market Outperform | — |
| Aug 13, 2026 | Wedbush | Outperform | — |
| Jul 28, 2026 | Wedbush | Outperform | — |
| Jun 15, 2026 | Citizens | Market Outperform | — |
No generated briefing is available yet.
Yahoo · Oct 27, 2026
Kura Oncology (KURA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · Oct 14, 2026
Kura Oncology (NASDAQ:KURA) and its newly formed affiliate Caspian Therapeutics outlined plans to develop KO-7246, an oral menin inhibitor, for diabetes, citing preclinical data that the companies said showed beta-cell expansion, improved glucose control and sustained effects after treatment ended.
SeekingAlpha · Oct 13, 2026
2026-10-13. The following slide deck was published by Kura Oncology, Inc.
SeekingAlpha · Oct 13, 2026
Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes October 13, 2026 4:30 PM EDTCompany...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning KURA.
